文献速递心外重症与机械循环支持

STS INTERMACS数据库:开展晚期心衰患者单臂试验的关键

STS INTERMACS Database: The Key to Conduct Single-Arm Trials in Advanced Heart Failure Patients.
PubMed 文献 · Ann Thorac Surg · 2021-04-27

该研究分析INTERMACS数据库能否为晚期心衰患者的单臂机械循环支持(MCS)试验建立客观性能标准和选择患者人群。纳入2014至2017年植入孤立左心室辅助装置的患者,按INTERMACS分级和休克状态分组,比较6个月和12个月结局。结果显示休克组与IM1-2组、非休克组与IM3-5组的一年生存率均相似,表明INTERMACS数据库可用于建立单臂试验的客观性能标准和同期对照组。

要点

  • INTERMACS数据库可为单臂MCS试验提供客观性能标准和同期对照组。

核心结论

  • INTERMACS数据库能成功建立客观性能标准和同期对照组,用于支持新型微创MCS的单臂试验及监管审批。
  • INTERMACS数据可可靠比较结局和不良事件。

研究设计与样本

  • 回顾性分析INTERMACS数据库,纳入2014至2017年植入孤立左心室辅助装置的IM1-2和IM3-5患者。
  • 按休克替代指标(ECMO、临时心室辅助装置、血管升压药输注)将两队列分为休克组和非休克组,共7907例。

主要发现

  • IM1-2组3909例,IM3-5组3998例,休克组3469例,非休克组3040例。
  • IM3-5组中11%患者被重新分类至休克组。

临床怎么用

  • 可利用INTERMACS数据库为单臂MCS试验设定客观性能标准和选择患者人群。
  • INTERMACS数据可用于可靠比较结局和不良事件,支持监管审批。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Safe introduction of novel mechanical circulatory support (MCS) devices into clinical practice is a challenging process. Single-arm trials using a control arm from existing database is an effective alternative that could be applied for regulatory approval. This study analyzes the capability of the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) database to establish objective performance criteria and select patient population that could be used for future single-arm MCS trials. METHODS: Patients with INTERMACS profiles IM1-2 and IM3-5, who underwent implantation of isolated left ventricular assist devices between 2014 and 2017, were included. Both cohorts were further stratified into shock and nonshock groups using surrogate markers of shock (extracorporeal membrane oxygenation, temporary ventricular assist device, vasopressor infusions). Survival, transplantation rates, adverse events, 6-minute walk test, and quality-of-life measures were obtained for all 4 groups at 6 and 12 months. RESULTS: Total of 7907 patients were divided into IM1-2 (n = 3909), IM3-5 (n = 3998), shock (n = 3469), and nonshock (n = 3040) groups. Recategorization occurred in 11% of patients from the IM3-5 group into the shock group. Overall, patients in the shock group had similar outcomes to the IM1-2 group (1-year survival: 86% vs 85%; P = .74). Patients in the nonshock group also had similar outcomes to the IM3-5 (1-year survival: 90% vs 90%; P = .43). CONCLUSIONS: The INTERMACS database can successfully establish objective performance criteria and concurrent control group for single-arm trials that could be used to support regulatory approval of new, less invasive MCS. INTERMACS data allow reliable comparisons of outcomes and adverse events.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Symalla T, Peev MP, Song T, et al. STS INTERMACS Database: The Key to Conduct Single-Arm Trials in Advanced Heart Failure Patients. Ann Thorac Surg. 2021. PMID: 33930360. doi:10.1016/j.athoracsur.2021.04.045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。